“Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s618. Accessed May 26, 2026. https://skin.dermsquared.com/skin/article/view/3822.